NCT06360601View on ClinicalTrials.gov

Intravenous Labetalol Versus Hydralazine in Preeclampsia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

November 20, 2024

Study Completion Date

December 20, 2024

Conditions
Preeclampsia Severe
Interventions
DRUG

Labetalol Injection

Labetalol intravenous infusion 20ml/hr

DRUG

HydrALAZINE Injection

Hydralazine intravenous infusion 5mg/hr

Trial Locations (1)

Unknown

RECRUITING

Tanta Univeristy hospitals, Tanta

All Listed Sponsors
lead

Tanta University

OTHER